J-Pharma and Uniphar advance nanvuranlat into global Phase III trial
Japanese biotech company J-Pharma (TSE Growth: 520A) and Ireland-based healthcare services group Uniphar have advanced nanvuranlat into global Phase III development for second-line biliary tract cancer, after reaching alignment with the US Food and Drug Administration (FDA) on the program’s regulatory path.
The companies said the agreement allows nanvuranlat, also known as JPH203, to move into a pivotal study without an additional Phase II trial. The first patients have now been randomized in the global Phase III study, which is being jointly managed by J-Pharma and Uniphar Development, Uniphar’s regulatory and clinical development division.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze